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mum tolerated dose was approached at 80 to 100 mg due to symp-
toms of chest discomfort and dyspnea. These results reveal a good 
safety margin to the highest dose selected for Phase 3 (20 mg).
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Introduction: Knowledge of adverse events (AEs) from biologic 
drugs used in pediatric population is limited. A recent Danish study 
analyzing AEs submitted to the Danish National Database indicated 
that off-label use of medicine in general to pediatric patients is associ-
ated with increased risk of AEs. The primary objective of the present 
study was to analyze the safety of off- and on-label use of biologic 
agents in a clinical sample of pediatric patients over a 3-year period 
and to identify potential risk factors associated with AEs.
Patients (or Materials) and Methods: A retrospective, longitudinal, 
study conducted in 1 pediatric department at Copenhagen University 
Hospital. Patients under the age of 18 years who received a minimum 
1 treatment with a biologic agent from January 1, 2009, through 
December 31, 2012, were included if they had been diagnosed with 
juvenile idiopathic arthritis (JIA) from 2009 to 2012. AEs and off-
label uses were identified by medical records review and classified 
according to the European Medical Agency guidelines. Multivariate 
logistic regression was used to investigate risk factors associated with 
an AE, and survival analysis was used to analyze time to an AE.
Results: 81 patients were included (65.4% females). Age ranged 
from 1 to 18 years (mean, 11.5 years). The 81 patients had a total 
of 133 courses of treatment with etanercept (49.6%), adalimumab 
(23.3%), infliximab (10.5%), golimumab (8.2%), tocilizumab 
(5.2%), and abatacept (3.0%). All patients were diagnosed with JIA 
(26 oligoarticular, 24 polyarticular, 2 systemic, 16 enthesitis-related 
JIA, and 16 JIA). Totally, 252 AEs were observed in 76% of the 
patients, 8 (3.2 %) of which were severe. 23.8% of the AEs had a 
treatment consequence (reduction in dose, treatment pause, discon-
tinuation of treatment) in 40.7% of the patients. After 200 days, 70% 
of all patients had experienced an AE. Gender, off-label use, type of 
drug, type of JIA, comedication, and comorbidity were not associ-
ated with an increased risk of AEs. Older age and severity of illness 
at time of treatment were the only significant predictors of AEs (P = 
0.0134, P < 0.0001). Off-label use was more likely with increasing 
number of treatment courses. Off-label use most often comprised of 
not recommended dose or indication. Time to an AE occurred did not 
differ with respect to type of drug or numbers of treatment courses.
Conclusion: AEs are frequent in this population of pediatric patients 
with juvenile idiopathic arthritis treated with biologic agents. Off-
label use was frequent but not associated with an increased risk of 
AEs.
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Introduction: Clinical trials (CT) and noninterventional trials 
(NIT) in Croatia are conducted in accordance with local laws (Drug 
law, and specific acts), and CT legislation is in accordance with 
European legislation. The Ministry of Health gives a final regula-
tory approval for CT. Since 2004, all clinical trials in Croatia have 
had to be reviewed by the Central Ethics Committee (CEC) and a 
favorable opinion must be issued before a clinical trial commences. 
Since December 2007, the CEC has also been responsible for issu-
ing opinions on noninterventional trials. During the trial evaluation 
procedure, CEC assesses scientific and ethical considerations of the 
trial. The aim of this analysis is to present the procedure of central 
evaluation and statistics of the CEC.
Patients (or Materials) and Methods: The database of the CEC is 
analyzed, and the trials are presented according to indication (topic), 
phase, and opinion issued after the first evaluation.
Results: According to a defined procedure and discussion, the CEC 
positive opinion has been given to 702 CT (since May 2004– 2012). 
During the last 5 years, 80 CT per year on average have had a posi-
tive opinion from the CEC. The greatest number of CT have been in 
the field of oncology (147), mental and behavioural disorders (95), 
and endocrine, nutritional, and metabolic diseases (88), and mostly 
Phase III trials. During the period of the last 5 years, CEC assessed 
67 NIT. The decisions after the first evaluation were conditionally 
positive or postponed opinion.
Conclusion: The model of centralized CT assessment through the 
Central Ethics Committee, as an independent body, has been con-
firmed during the investigated period as appropriate for Croatia. 
Furthermore, CEC assessment of NIT has also been confirmed as 
useful because this procedure, as a gatekeeper, prevents conducting 
the trials only for marketing purposes and allows in Croatia only 
NIT of certain quality and scientific merit.
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Introduction: Older people have often been excluded from preau-
thorization trials. Therefore, the regulatory ICH E7 guideline requires 
a minimal number of older subjects for trials regarding diseases pri-
marily related to aging (> 50% of database aged 65+) and for dis-
eases not typical for, but present in old age (> 100 subjects 65+). 
The study objective was to analyze the number of older people in 
trials of recently authorized drugs indicated for diseases that regularly 
present in old age.
Patients (or Materials) and Methods: Eligible drugs for this descrip-
tive study were registered by the European Medicines Agency 
between 2008 and 2011. Chosen indications: prevention of venous 
thromboembolism after replacement arthroplasty (dabigatran, rivar-
oxaban), osteoporosis (lasofoxifene, bazedoxifene, denosumab), 
atrial fibrillation (dronedarone, vernakalant), diabetes mellitus type 
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II (liraglutide, saxagliptin), depression (agomelatine), bipolar dis-
order (asenapine), and epilepsy (eslicarbazepine). Data of all Phase 
II and III trials were identified in the European public assessment 
reports, the WHO Trials Registry, and PubMed. Outcome measures: 
the number of randomized subjects and the number of those aged 65 
and 75 years and older. Trials with missing data were not included 
in the calculation of that outcome. Rates of trials giving information 
about the number of older subjects and the proportions of older 
people were calculated.
Results: The number of people aged 65+ and 75+ was available in 
39% and 48% of the 116 included trials, respectively. The propor-
tion of older people varied from 0% to 93%. In trials for indications 
primarily related to aging (n = 7), 47.1% of the subjects were 65+ 
(median, 2681; range, 524–5848); 20.6% were 75+ (median, 1575; 
range, 216–5848). In trials for indications not specific for, but present 
in old age (n = 5), 7.5% of the subjects were 65+ (median, 108; range, 
14–887); 0.9% were aged 75 and older (median, 26; range, 0–83).
Conclusion: This study on the number of older subjects in clinical 
trials of recently authorized drugs shows that in trials for indications 
primarily related to aging, almost half of the randomized subjects are 
aged 65 and older. In trials for indications not specific for, but present 
in old age, the number and especially the proportion of older subjects 
is limited. So, serious improvement concerning the inclusion of the 
older target population is needed for drugs intended for younger as 
well as for older patients.
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Introduction: A single inhaled dose of laninamivir octanoate (LO), 
a long-acting neuraminidase inhibitor, exhibits efficacy to treat both 
adult and pediatric patients with influenza virus infection. However, 
the relation between the intrapulmonary pharmacokinetics (PK) of 
LO and laninamivir, an active metabolite, and its long-lasting efficacy 
has not fully been investigated. Intrapulmonary pharmacokinetics 
in healthy volunteers and the intracellular drug disposition in mice 
were evaluated to clarify the potential mechanism for the prolonged 
high intrapulmonary retention of laninamivir, which would support 
its long-lasting efficacy.
Patients (or Materials) and Methods: A single-center, open-label 
study was performed in adult healthy volunteers. Seven subgroups of 
5 subjects each underwent bronchoalveolar lavage (BAL) at specified 
time intervals from 4 to 240 hours after a single inhaled administra-
tion of LO (40 mg). Plasma, BAL fluid, and alveolar macrophage 
(AM) were analyzed to determine laninamivir and LO concentrations 
using validated LC-MS/MS methods. The concentrations in epithe-
lial lining fluid (ELF) were calculated by the urea diffusion method. 
Microautoradiographic localization in the respiratory tissues was 
evaluated after a single intranasal administration of radiolabeled LO 
to mice. In addition, the disposition of LO and laninamivir was evalu-
ated by measuring the drug uptake and release in primary cultured 
mouse airway epithelial cells.
Results: In healthy volunteers, the peak plasma concentrations of 
laninamivir occurred at 3.5 hours after inhalation and decreased 
with the half-life of 45.7 hours. Laninamivir concentrations in ELF 
and AM were much higher than those in plasma and lasted for 240 
hours. Cmax of laninamivir in ELF from first BAL was 8.6 μ g/mL and 
laninamivir in ELF decreased with longer half-life (~6 days) than that 
in plasma. Laninamivir concentrations in ELF notably exceeded the 
IC50 values for viral neuraminidase at all time points examined. In 
mice, the labeled LO derived activity after an intranasal administra-
tion mainly located on the epithelial cells for a long period. The 
uptake of LO in airway epithelial cells increased without any appar-
ent saturation even at the highest concentration tested (1000 μ M). 
Furthermore, the intracellular laninamivir was released very slowly 
into the drug-free medium, which was regarded as a rate-limiting 
step in the cellular retention.
Conclusion: ELF concentration profiles and prolonged high intrapul-
monary retention of laninamivir support its long-lasting efficacy to 
treat patients with influenza virus infection by the single inhalation.
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Introduction: Busulfan, an alkylating agent, is used in combination 
with other drugs in patients undergoing stem cell transplantation. 
Busulfan presents a very narrow therapeutic window, which has been 
linked to various adverse events. Therapeutic monitoring protocols 
have been developed to allow the individualization of the dose, but 
the dose selection and the sampling time for pharmacokinetics are 
based on empirical evidence. Consequently, target exposure cannot be 
warranted. The aim of this investigation was to determine the optimal 
sampling scheme and develop a model-based dosing algorithm for 
busulfan in stem cell transplantation patients.
Patients (or Materials) and Methods: Clinical data (n = 29) from 
an ongoing study were used for the purposes our analysis. A 1-com-
partment model was selected as basis for sampling optimization and 
subsequent evaluation of a suitable dosing algorithm. Internal and 
external model validation procedures were performed before the opti-
mization steps using ED-optimality criteria. Clearance and volume 
of distribution were considered as parameters of interest. The final 
sampling scheme and dosing algorithm were based on the deviation 
from target exposure range, as determined by AUC(0–6).
Results: A 1-compartment model was found to describe busulfan 
exposure after oral administration, with ideal body weight (IBW) 
and alanine transferase (ALT) as covariates on clearance. A sparse 
sampling scheme with five samples per patient (t = 0.5, 2.25, 3, 4, and 
5 hours after dose) was found to be sufficient for the characterization 
